

Francesco Forconi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3454135/publications.pdf>

Version: 2024-02-01

267
papers

10,973
citations

41627

51
h-index

38517

99
g-index

272
all docs

272
docs citations

272
times ranked

9788
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>BRAF</i> Mutations in Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2011, 364, 2305-2315.	13.9	949
2	Analysis of the chronic lymphocytic leukemia coding genome: role of <i>NOTCH1</i> mutational activation. <i>Journal of Experimental Medicine</i> , 2011, 208, 1389-1401.	4.2	565
3	Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 1403-1412.	0.6	420
4	Mutations of <i>NOTCH1</i> are an independent predictor of survival in chronic lymphocytic leukemia. <i>Blood</i> , 2012, 119, 521-529.	0.6	394
5	Mutations of the <i>SF3B1</i> splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. <i>Blood</i> , 2011, 118, 6904-6908.	0.6	342
6	The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. <i>Blood</i> , 2011, 117, 3391-3401.	0.6	316
7	Perturbation of the normal immune system in patients with CLL. <i>Blood</i> , 2015, 126, 573-581.	0.6	290
8	The Prognostic Value of <i>TP53</i> Mutations in Chronic Lymphocytic Leukemia Is Independent of <i>Del17p13</i> : Implications for Overall Survival and Chemorefractoriness. <i>Clinical Cancer Research</i> , 2009, 15, 995-1004.	3.2	284
9	Disruption of <i>BIRC3</i> associates with fludarabine chemorefractoriness in <i>TP53</i> wild-type chronic lymphocytic leukemia. <i>Blood</i> , 2012, 119, 2854-2862.	0.6	257
10	Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. <i>British Journal of Haematology</i> , 2009, 145, 733-740.	1.2	229
11	Effect of a p210 multi-peptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. <i>Lancet</i> , 2005, 365, 657-662.	6.3	221
12	Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. <i>Blood</i> , 2013, 122, 2673-2682.	0.6	208
13	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 126, 1921-1924.	0.6	197
14	Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2722-2729.	0.8	197
15	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. <i>Blood</i> , 2017, 129, 553-560.	0.6	193
16	Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. <i>Clinical Cancer Research</i> , 2009, 15, 4415-4422.	3.2	189
17	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. <i>Blood</i> , 2011, 117, 1595-1604.	0.6	173
18	Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the <i>BRAF-V600E</i> mutation. <i>Blood</i> , 2012, 119, 192-195.	0.6	166

#	ARTICLE	IF	CITATIONS
19	Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. <i>Lancet</i> , The, 2005, 365, 657-662.	6.3	138
20	The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. <i>British Journal of Haematology</i> , 2009, 146, 64-75.	1.2	136
21	Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing. <i>Clinical Cancer Research</i> , 2015, 21, 4174-4183.	3.2	129
22	Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. <i>Lancet Haematology</i> , the, 2020, 7, e112-e121.	2.2	119
23	Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. <i>Blood</i> , 2009, 114, 4696-4702.	0.6	114
24	High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. <i>Leukemia</i> , 1997, 11, 2075-2078.	3.3	113
25	Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 4902-4905.	0.6	113
26	Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. <i>British Journal of Haematology</i> , 2009, 144, 492-506.	1.2	106
27	Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. <i>Blood</i> , 2002, 100, 1505-1507.	0.6	105
28	The occurrence and significance of V gene mutations in B cell-derived human malignancy. <i>Advances in Cancer Research</i> , 2001, 83, 81-116.	1.9	95
29	Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. <i>Haematologica</i> , 2010, 95, 1792-1796.	1.7	91
30	Different impact of <i>NOTCH1</i> and <i>SF3B1</i> mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. <i>British Journal of Haematology</i> , 2012, 158, 426-429.	1.2	90
31	The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1. <i>Leukemia</i> , 2016, 30, 351-360.	3.3	88
32	The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy. <i>Haematologica</i> , 2014, 99, 1138-1148.	1.7	87
33	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2020, 135, 1859-1869.	0.6	86
34	Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch. <i>Blood</i> , 2004, 104, 3312-3317.	0.6	84
35	The normal IGHV1-69-derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL. <i>Blood</i> , 2010, 115, 71-77.	0.6	83
36	<i>MGA</i> , a suppressor of <i>MYC</i> , is recurrently inactivated in high risk chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1087-1090.	0.6	81

#	ARTICLE	IF	CITATIONS
37	Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. <i>British Journal of Haematology</i> , 2008, 142, 529-537.	1.2	78
38	Tumor cells of hairy cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing. <i>Blood</i> , 2001, 98, 1174-1181.	0.6	77
39	IL-4 enhances expression and function of surface IgM in CLL cells. <i>Blood</i> , 2016, 127, 3015-3025.	0.6	76
40	Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients. <i>Journal of Translational Medicine</i> , 2009, 7, 1.	1.8	74
41	Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. <i>Haematologica</i> , 2001, 86, 1046-50.	1.7	73
42	Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia. <i>Leukemia</i> , 2016, 30, 2179-2186.	3.3	69
43	STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy. <i>Cancer Research</i> , 2017, 77, 3619-3631.	0.4	69
44	13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 633-643.	1.5	67
45	Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. <i>Blood</i> , 2020, 136, 2918-2926.	0.6	67
46	Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 448-456.	1.7	64
47	Comprehensive characterization of IGHV3-21 ⁺ expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. <i>Blood</i> , 2007, 109, 2989-2998.	0.6	62
48	Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion. <i>British Journal of Haematology</i> , 2008, 143, 532-536.	1.2	58
49	Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function. <i>Blood</i> , 2013, 122, 2664-2672.	0.6	58
50	Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation. <i>Blood</i> , 2016, 127, 449-457.	0.6	56
51	Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL. <i>Blood</i> , 2016, 128, 816-826.	0.6	54
52	Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. <i>Leukemia and Lymphoma</i> , 2011, 52, 75-78.	0.6	53
53	DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. <i>Blood</i> , 2015, 125, 1922-1931.	0.6	53
54	Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis. <i>British Journal of Haematology</i> , 2019, 185, 656-669.	1.2	53

#	ARTICLE	IF	CITATIONS
55	Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. <i>Blood</i> , 2010, 116, 584-592.	0.6	51
56	The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 2313-2324.	3.2	51
57	S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis. <i>Blood</i> , 2012, 120, 4391-4399.	0.6	50
58	The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. <i>Cancer</i> , 2007, 110, 2240-2247.	2.0	47
59	Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia. <i>Blood</i> , 2010, 115, 3726-3736.	0.6	47
60	The coexistence of chronic lymphocytic leukemia and myeloproliferative neoplasms: A retrospective multicentric GIMEMA experience. <i>American Journal of Hematology</i> , 2011, 86, 1007-1012.	2.0	47
61	Genomic profiling of Richter's syndrome: recurrent lesions and differences with <i>de novo</i> diffuse large B-cell lymphomas. <i>Hematological Oncology</i> , 2010, 28, 62-67.	0.8	46
62	Expression of Mutated <i>IGHV3-23</i> Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features. <i>Clinical Cancer Research</i> , 2010, 16, 620-628.	3.2	44
63	HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism. <i>Haematologica</i> , 2014, 99, 888-896.	1.7	43
64	Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. <i>ELife</i> , 2014, 3, .	2.8	43
65	The Meaning and Relevance of B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia. <i>Seminars in Hematology</i> , 2014, 51, 158-167.	1.8	42
66	Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. <i>Journal of Translational Medicine</i> , 2009, 7, 76.	1.8	41
67	Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2011, 154, 590-599.	1.2	40
68	Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey. <i>Leukemia</i> , 1997, 11, 629-632.	3.3	39
69	Origins of the malignant clone in typical Waldenstrom's macroglobulinemia. <i>Seminars in Oncology</i> , 2003, 30, 136-141.	0.8	37
70	Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia. <i>Hematological Oncology</i> , 2008, 26, 247-251.	0.8	36
71	Hairy cell leukaemia: biological and clinical overview from immunogenetic insights. <i>Hematological Oncology</i> , 2011, 29, 55-66.	0.8	35
72	Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK. <i>Blood</i> , 2014, 124, 3101-3109.	0.6	34

#	ARTICLE	IF	CITATIONS
73	The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the E μ -TCL1 mouse model. <i>Blood</i> , 2015, 125, 4032-4041.	0.6	34
74	Endothelin-1 Promotes Survival and Chemoresistance in Chronic Lymphocytic Leukemia B Cells through ETA Receptor. <i>PLoS ONE</i> , 2014, 9, e98818.	1.1	33
75	High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia. <i>British Journal of Haematology</i> , 2008, 141, 622-630.	1.2	32
76	Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia. <i>Haematologica</i> , 2008, 93, 697-705.	1.7	32
77	Absence of surface CD27 distinguishes hairy cell leukemia from other leukemic B-cell malignancies. <i>Haematologica</i> , 2005, 90, 266-8.	1.7	32
78	The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma. <i>Blood</i> , 2011, 117, 2405-2413.	0.6	30
79	B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the <i>IGHV3</i> subgroup gene usage. <i>British Journal of Haematology</i> , 2011, 153, 3-14.	1.2	30
80	Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , 2011, 29, 91-99.	0.8	30
81	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. <i>Haematologica</i> , 2018, 103, 1209-1217.	1.7	30
82	A variant of the <i>LRP4</i> gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome. <i>British Journal of Haematology</i> , 2011, 152, 284-294.	1.2	28
83	Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis. <i>International Journal of Cancer</i> , 2012, 130, 3006-3010.	2.3	28
84	Hairy cell leukemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal unrepresentative origins. <i>Leukemia</i> , 2013, 27, 241-245.	3.3	28
85	Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification. <i>Haematologica</i> , 2017, 102, 968-971.	1.7	28
86	IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus. <i>Leukemia</i> , 2017, 31, 1686-1694.	3.3	28
87	Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. <i>Leukemia</i> , 2021, 35, 1864-1872.	3.3	28
88	<i>MDM4 (MDMX)</i> is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53 ^{wild-type} CLL with a poor cytotoxic response to Nutlin-3. <i>British Journal of Haematology</i> , 2010, 150, 237-239.	1.2	27
89	2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders. <i>European Journal of Haematology</i> , 1997, 58, 46-50.	1.1	26
90	Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial. <i>Blood</i> , 2021, 138, 642-642.	0.6	26

#	ARTICLE	IF	CITATIONS
91	Clinical heterogeneity of <i>de novo</i> 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. <i>Hematological Oncology</i> , 2013, 31, 88-95.	0.8	25
92	Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. <i>Blood</i> , 2002, 100, 1505-7.	0.6	25
93	Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications. <i>Leukemia</i> , 2020, 34, 462-477.	3.3	24
94	Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. <i>Experimental Hematology</i> , 2014, 42, 126-136.e1.	0.2	23
95	Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients. <i>Clinical Cancer Research</i> , 2019, 25, 2503-2512.	3.2	23
96	IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution. <i>Blood</i> , 2020, 135, 834-844.	0.6	23
97	IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia. <i>Journal of Translational Medicine</i> , 2012, 10, 18.	1.8	21
98	Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses. <i>Immunology</i> , 2002, 107, 39-45.	2.0	20
99	Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. <i>British Journal of Haematology</i> , 2010, 151, 435-439.	1.2	20
100	Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype. <i>Hematological Oncology</i> , 2012, 30, 46-49.	0.8	20
101	Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3K γ inhibition. <i>Leukemia</i> , 2015, 29, 744-747.	3.3	20
102	Shaving Is an Epiphenomenon of Type I and II Anti-CD20-Mediated Phagocytosis, whereas Antigenic Modulation Limits Type I Monoclonal Antibody Efficacy. <i>Journal of Immunology</i> , 2018, 201, 1211-1221.	0.4	20
103	Exploring the pathways to chronic lymphocytic leukemia. <i>Blood</i> , 2021, 138, 827-835.	0.6	20
104	Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study. <i>Blood</i> , 2018, 132, 182-182.	0.6	20
105	Promoter methylation patterns in Richter syndrome affect stem cell maintenance and cell cycle regulation and differ from <i>de novo</i> diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2013, 163, 194-204.	1.2	19
106	The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <lt;97% identity and similar to those with 98% identity. <i>British Journal of Haematology</i> , 2016, 173, 127-136.	1.2	19
107	The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 918-923.	1.2	19
108	Revisiting the definition of somatic mutational status in B-cell tumors: does 98% homology mean that a VH-gene is unmutated?. <i>Leukemia</i> , 2004, 18, 882-883.	3.3	18

#	ARTICLE	IF	CITATIONS
109	Complete molecular remission induced by concomitant Cladribine + Rituximab treatment in a case of multi-resistant Hairy Cell Leukemia. <i>Leukemia and Lymphoma</i> , 2007, 48, 2441-2443.	0.6	18
110	Alternative methods of cladribine administration. <i>Leukemia and Lymphoma</i> , 2011, 52, 34-37.	0.6	18
111	Genome-wide high resolution <sc>DNA</sc> profiling of hairy cell leukaemia. <i>British Journal of Haematology</i> , 2013, 162, 566-569.	1.2	18
112	Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. <i>The Hematology Journal</i> , 2004, 5, 472-474.	2.0	17
113	Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL. <i>Blood</i> , 2020, 135, 411-428.	0.6	17
114	A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis. <i>Blood</i> , 2010, 116, 2462-2462.	0.6	17
115	Analysis of Parameters Predicting Treatment Efficacy and Outcome In Patients with Hairy Cell Leukemia (HCL) Receiving Subcutaneous Cladribine In the ICGHCL2004 Protocol (by the Italian Cooperative) <i>TJ ETQq1 1 0.784314 rgBT7Overlook</i>	0.6	17
116	Richter Syndrome (RS): Genome-Wide Promoter Methylation Profile Differs From De Novo Diffuse Large B-Cell Lymphoma (DLBCL) and Affects Genes Involved in Stem-Cell Maintenance and TP53 Pathway. <i>Blood</i> , 2011, 118, 1359-1359.	0.6	17
117	Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia. <i>Leukemia</i> , 2006, 20, 142-143.	3.3	16
118	Defining origins of malignant B cells: a new circulating normal human IgM+D+ B-cell subset lacking CD27 expression and displaying somatically mutated IGHV genes as a relevant memory population. <i>Leukemia</i> , 2009, 23, 2075-2080.	3.3	16
119	Genome-wide promoter methylation of hairy cell leukemia. <i>Blood Advances</i> , 2019, 3, 384-396.	2.5	16
120	Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. <i>Haematologica</i> , 2012, 97, 849-853.	1.7	14
121	Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCLv). <i>British Journal of Haematology</i> , 2020, 191, 730-737.	1.2	14
122	Targeted inhibition of eIF4A suppresses B-cell receptor-induced translation and expression of MYC and MCL1 in chronic lymphocytic leukemia cells. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 6337-6349.	2.4	14
123	Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment. <i>Blood</i> , 2022, 140, 630-643.	0.6	14
124	Towards the pharmacotherapy of hairy cell leukaemia. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 1523-1533.	0.9	13
125	Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH. <i>Annals of Oncology</i> , 2013, 24, 1378-1384.	0.6	13
126	Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells. <i>Clinical Cancer Research</i> , 2020, 26, 1700-1711.	3.2	13

#	ARTICLE	IF	CITATIONS
127	VH and VL Genes in Hairy Cell Leukemia Reveal a Dynamic On-Going Modification of the Surface B-Cell Receptor.. Blood, 2005, 106, 287-287.	0.6	13
128	Massive intravascular hemolysis: a fatal complication of Clostridium perfringens septicemia in a patient with acute lymphoblastic leukemia. Leukemia and Lymphoma, 2005, 46, 793-793.	0.6	12
129	Emerging drugs in chronic myelogenous leukaemia. Expert Opinion on Emerging Drugs, 2006, 11, 651-664.	1.0	12
130	PI3K inhibition elicits anti-leukemic effects through Bim-dependent apoptosis. Leukemia, 2017, 31, 1423-1433.	3.3	12
131	BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia. Leukemia, 2020, 34, 640-644.	3.3	12
132	Combination therapies to improve the long-term outcome in hairy cell leukemia. Leukemia and Lymphoma, 2009, 50, 18-22.	0.6	11
133	The IGHV1-69/IGHJ3 recombinations of unmutated CLL are distinct from those of normal B cells. Blood, 2012, 119, 2106-2109.	0.6	11
134	Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial. Blood, 2020, 136, 17-18.	0.6	11
135	Acalabrutinib in patients (pts) with Waldenström macroglobulinemia (WM).. Journal of Clinical Oncology, 2018, 36, 7501-7501.	0.8	11
136	Thrombotic Thrombocytopenic Purpura Secondary to an Occult Adenocarcinoma. Oncologist, 2005, 10, 299-300.	1.9	10
137	Overlapping morphologic and immunophenotypic profiles in small B-cell lymphoma. A report of two cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 320-327.	1.4	10
138	Control of Residual Disease in Imatinib Treated Chronic Myeloid Leukemia Patients with Peptide Vaccinations: 2 Years Follow up of CMLVAX100 Trial.. Blood, 2005, 106, 167-167.	0.6	10
139	CD30 positive (non-anaplastic) peripheral T-cell lymphoma of the thyroid gland. Haematologica, 1999, 84, 946-8.	1.7	10
140	Mutation of BAX occurs infrequently in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. , 2000, 27, 177-182.		9
141	Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort. Leukemia and Lymphoma, 2010, 51, 822-838.	0.6	9
142	Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array. British Journal of Haematology, 2012, 156, 354-357.	1.2	9
143	Higher levels of reactive oxygen species are associated with anergy in chronic lymphocytic leukemia. Haematologica, 2015, 100, e265-e268.	1.7	9
144	Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia. Nature Communications, 2021, 12, 665.	5.8	9

#	ARTICLE	IF	CITATIONS
145	Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior. <i>Blood</i> , 2021, 138, 1570-1582.	0.6	9
146	Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas. <i>Haematologica</i> , 1999, 84, 716-20.	1.7	9
147	Molecular Cytogenetic Analysis of B-CLL Patients with Aggressive Disease. <i>Hematology</i> , 2004, 9, 383-385.	0.7	8
148	Are surrogates of IGHV gene mutational status useful in B-cell chronic lymphocytic leukemia? The example of Septin-10. <i>Leukemia</i> , 2008, 22, 224-226.	3.3	8
149	Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis. <i>Leukemia and Lymphoma</i> , 2011, 52, 15-23.	0.6	8
150	Variant B Cell Receptor Isotype Functions Differ in Hairy Cell Leukemia with Mutated BRAF and IGHV Genes. <i>PLoS ONE</i> , 2014, 9, e86556.	1.1	8
151	Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRF FLAIR Trial. <i>Blood</i> , 2021, 138, 2636-2636.	0.6	8
152	Incidence of novel N-glycosylation sites in the B-cell receptor of lymphomas associated with immunodeficiency. <i>British Journal of Haematology</i> , 2004, 124, 604-609.	1.2	7
153	Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide. <i>Leukemia and Lymphoma</i> , 2018, 59, 423-433.	0.6	7
154	PEITC-mediated inhibition of mRNA translation is associated with both inhibition of mTORC1 and increased eIF2 γ phosphorylation in established cell lines and primary human leukemia cells. <i>Oncotarget</i> , 2016, 7, 74807-74819.	0.8	7
155	Rituximab Plus Chlorambucil As Initial Treatment for Elderly Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Pre-Treatment Biological Characteristics and Gene Expression Patterns on Response to Treatment. <i>Blood</i> , 2011, 118, 294-294.	0.6	6
156	Impact of the host genetic background on prognosis of chronic lymphocytic leukemia. <i>Blood</i> , 2010, 115, 1106-1107.	0.6	5
157	Insight into the behavior of hairy cell leukemia by immunogenetic analysis. <i>Leukemia and Lymphoma</i> , 2011, 52, 103-107.	0.6	5
158	Lack of allelic exclusion by secondary rearrangements of tumour B-cell receptor light chains in hairy cell leukaemia. <i>Hematological Oncology</i> , 2011, 29, 31-37.	0.8	5
159	Three years of ibrutinib in CLL. <i>Blood</i> , 2015, 125, 2455-2456.	0.6	5
160	Analysis of Toxicity and Efficacy of Subcutaneous Cladribine at Reduced or Standard Doses (Five) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 I by the Italian Cooperative Group on Hcl. <i>Blood</i> , 2010, 116, 701-701.	0.6	5
161	B-cell receptor signaling induces proteasomal degradation of PDCD4 via MEK1/2 and mTORC1 in malignant B cells. <i>Cellular Signalling</i> , 2022, 94, 110311.	1.7	5
162	KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer Activity. <i>Journal of Immunology</i> , 2022, 209, 379-390.	0.4	5

#	ARTICLE	IF	CITATIONS
163	Trisomy 12 and t(14;22)(q32;q11) in a Patient with B-cell Chronic Lymphocytic Leukemia. <i>Hematology</i> , 2004, 9, 405-407.	0.7	4
164	DC-SIGN binding to mannosylated B-cell receptors in follicular lymphoma down-modulates receptor signaling capacity. <i>Scientific Reports</i> , 2021, 11, 11676.	1.6	4
165	High Surface IgM Levels Associate with Shorter Response Duration and Bypass of the BTK Blockade during Ibrutinib Therapy in CLL Patients. <i>Blood</i> , 2019, 134, 1752-1752.	0.6	4
166	SNP6 Array Better Defines Chronic Lymphocytic Leukemia (CLL) Prognostic Groups. <i>Blood</i> , 2010, 116, 3611-3611.	0.6	4
167	Mutations of the SF3B1 splicing Factor in Chronic Lymphocytic Leukemia: Association with Progression and Fludarabine-Refractoriness. <i>Blood</i> , 2011, 118, 464-464.	0.6	4
168	Biological and Clinical Insight from Analysis of the Tumor B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2022, 14, 663.	1.7	4
169	Pilot Study of Gemtuzumab Ozogamicin (GO), Fludarabine, Cytarabine and Idarubicin Combined Regimen (GO-FLAI) as First-Line Induction Therapy plus GO Alone as Consolidation Therapy for Elderly Acute Myeloid Leukemia Patients. <i>Acta Haematologica</i> , 2007, 118, 7-9.	0.7	3
170	A pilot monocentric analysis of efficacy and safety of Fludarabine+Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 dysfunction. <i>British Journal of Haematology</i> , 2011, 154, 271-274.	1.2	3
171	Five years of ibrutinib in CLL. <i>Blood</i> , 2018, 131, 2280-2281.	0.6	3
172	Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells. <i>Clinical Cancer Research</i> , 2021, 27, 5647-5659.	3.2	3
173	The Syk/Jak Inhibitor Cerdulatinib (PRT062070) Shows Promising Preclinical Activity in Chronic Lymphocytic Leukemia By Antagonising B Cell Receptor and Microenvironmental Signalling. <i>Blood</i> , 2015, 126, 1716-1716.	0.6	3
174	TP53 Mutations, the Most Frequent Genetic Lesion in Richter Syndrome, Represent An Independent Predictor of Survival Post Transformation.. <i>Blood</i> , 2009, 114, 670-670.	0.6	3
175	High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL. <i>Blood Advances</i> , 2022, 6, 5494-5504.	2.5	3
176	Lymphoma-Specific Subversion of B-Cell Receptor Signaling By Macrophage Lectins. <i>Blood</i> , 2018, 132, 2865-2865.	0.6	2
177	Hairy Cell Leukemias (HCL) with Unmutated V-Genes Have a Poorer Response to Single Agent 2CdA Than HCL with Mutated V-Genes.. <i>Blood</i> , 2006, 108, 2327-2327.	0.6	2
178	Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0). <i>Blood</i> , 2010, 116, 1371-1371.	0.6	2
179	Efficacy and Safety of a First Line Combined Therapeutic Approach for Young CLL Patients with Advanced or Progressive Disease Stratified According to the Biologic Features: First Analysis of the GIMEMA Multicenter Study LLC0405. <i>Blood</i> , 2010, 116, 2471-2471.	0.6	2
180	Global and MYC-Specific Translation Is Enhanced in Activated Chronic Lymphocytic Leukemia Cells Carrying NOTCH1 C.7541_7542delct Mutations. <i>Blood</i> , 2016, 128, 970-970.	0.6	2

#	ARTICLE	IF	CITATIONS
181	A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the induction phase.. Journal of Clinical Oncology, 2011, 29, 6629-6629.	0.8	2
182	Large Genomic Aberrations Are Independent Prognosticators of A Shorter Time to First Treatment (TTT) in Chronic Lymphocytic Leukemia (CLL) Patients with A Normal FISH. Blood, 2012, 120, 3906-3906.	0.6	2
183	In Vitro and in Vivo Evidence of an Anti-Angiogenic Effect of Lenalidomide in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 1782-1782.	0.6	2
184	Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype. Haematologica, 1998, 83, 853-4.	1.7	2
185	B-cell receptor dependent phagocytosis and presentation of particulate antigen by chronic lymphocytic leukemia cells. Exploration of Targeted Anti-tumor Therapy, 2022, 3, 37-49.	0.5	2
186	<i>IGHD3</i> fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia. British Journal of Haematology, 2010, 149, 299-302.	1.2	1
187	Predicting the clinical course of Hodgkin lymphoma. Nature Reviews Clinical Oncology, 2010, 7, 1-1.	12.5	1
188	Acalabrutinib in Patients (pts) with Waldenström Macroglobulinemia (WM). Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S285-S286.	0.2	1
189	International Prognostic Score (IPS-A) for Patients with Early Stage Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S278.	0.2	1
190	INTERNATIONAL PROGNOSTIC SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (IPS-A). Hematological Oncology, 2019, 37, 81-82.	0.8	1
191	PS1125 LINKING MICROENVIRONMENTAL SIGNALS TO METABOLIC SWITCHES AND IBRUTINIB RESPONSE IN CHRONIC LYMPHOCYTIC LEUKEMIA. HemaSphere, 2019, 3, 509-510.	1.2	1
192	NOTCH1 Stabilization By PEST Mutations Enhances IgM-Mediated Activity in Chronic Lymphocytic Leukemia. Blood, 2018, 132, 1832-1832.	0.6	1
193	Multicentre Genome Wide Association Study Identifies Risk Alleles for Progressive Chronic Lymphocytic Leukaemia. Blood, 2019, 134, 1740-1740.	0.6	1
194	Mannosylation of the Tumor Immunoglobulin Variable Region Informs Cell of Origin and Environmental Interactions in DLBCL Subsets. Blood, 2019, 134, 1505-1505.	0.6	1
195	Array-CGH Identifies Both Common and Subtype-Specific Genomic Aberrations in Marginal Zone Lymphomas. Blood, 2008, 112, 622-622.	0.6	1
196	Characterising the Burden of Chronic Lymphocytic Leukemia in Fludarabine-Ineligible Patients in Spain, Italy, and the United Kingdom (UK): A Retrospective Observational Study. Blood, 2014, 124, 2646-2646.	0.6	1
197	IgM+ B-Cells Lacking CD27 Expression Display Somatic Mutated Ig VH Genes and Define a New Memory Population.. Blood, 2007, 110, 2630-2630.	0.6	1
198	Chronic Lymphocytic Leukemia Subset Expressing Mutated IGHV3-23 Has Peculiar Clinical and Biological Features.. Blood, 2009, 114, 1256-1256.	0.6	1

#	ARTICLE	IF	CITATIONS
199	Molecular History of Richter Syndrome: Origin From a Common Ancestor Cell Already Present at Chronic Lymphocytic Leukemia Diagnosis. <i>Blood</i> , 2010, 116, 2425-2425.	0.6	1
200	SNP-Arrays Provide New Insights Into the Pathogenesis of Richter Syndrome (RS). <i>Blood</i> , 2011, 118, 263-263.	0.6	1
201	Deep-Sequencing Reveals the Molecular Landscape of Splenic Marginal Zone Lymphoma: Biological and Clinical Implications. <i>Blood</i> , 2014, 124, 76-76.	0.6	1
202	Chemical Activation of the SHIP1 Inositol Lipid Phosphatase: A Novel Therapeutic Strategy to Suppress B-Cell Receptor Signaling and CXCR4 Expression in Malignant Human B Cells. <i>Blood</i> , 2016, 128, 2037-2037.	0.6	1
203	Abstract 1871: Development of pelorol analogues to activate the SHIP1 lipid phosphatase; a novel paradigm to suppress B-cell receptor signaling in human B-cell cancers. , 2018, , .		1
204	Linking Microenvironmental Signals to Metabolic Switches and Drug Responses in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 479-479.	0.6	1
205	Effects of Ibrutinib on Metabolic Alterations and Micro-Environmental Signalling in Chronic Lymphocytic Leukaemia. <i>Blood</i> , 2020, 136, 36-37.	0.6	1
206	BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells. <i>Cellular Signalling</i> , 2022, 96, 110358.	1.7	1
207	SELECTIVE INFLUENCES IN THE B-CELL RECEPTOR IMMUNOGLOBULIN HEAVY AND LIGHT CHAIN IN HAIRY CELL LEUKEMIA. <i>Journal of the Siena Academy of Sciences</i> , 2009, 1, .	0.0	0
208	SELECTIVE INFLUENCES IN THE B-CELL RECEPTOR IMMUNOGLOBULIN HEAVY AND LIGHT CHAIN IN HAIRY CELL LEUKEMIA. <i>Journal of the Siena Academy of Sciences</i> , 2009, 1, 18.	0.0	0
209	B-cell chronic lymphocytic leukemia. , 0, , 786-792.		0
210	Mutations of BRAF and BIRC3 Identify a Subgroup of Chronic Lymphocytic Leukemia with Very Poor Prognosis upon FCR Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S11-S12.	0.2	0
211	Hedgehog activation in CLL. <i>Blood</i> , 2019, 133, 2628-2630.	0.6	0
212	The Hydropathy Index of the HCDR3 Region of the B-Cell Receptor Identifies Two Subgroups of IGHV-Mutated Chronic Lymphocytic Leukemia Patients With Distinct Outcome. <i>Frontiers in Oncology</i> , 2021, 11, 723722.	1.3	0
213	Phase II Pilot Study of Gemtuzumab Ozogamicin (GO), Fludarabine, Cytarabine and Idarubicin Combined Regimen as Induction Therapy Plus GO Alone as Consolidation Therapy for Elderly Acute Myeloid Leukemia Patients.. <i>Blood</i> , 2005, 106, 4613-4613.	0.6	0
214	ZAP-70 Expression in T Cells of B-Cell Chronic Lymphocytic Leukaemia: Correlation with Negative Prognostic Factors of the Disease.. <i>Blood</i> , 2005, 106, 4998-4998.	0.6	0
215	LAT Down-Regulation in T Lymphocytes from B-Cell Chronic Lymphocytic Leukemia: A Possible Mechanism for T Cell Incompetence.. <i>Blood</i> , 2006, 108, 3882-3882.	0.6	0
216	Identification of New Recurrent Lesions and Clinical Subsets by Genome-Wide DNA Profiling in Chronic Lymphocytic Leukemia with 17p Deletion.. <i>Blood</i> , 2007, 110, 4696-4696.	0.6	0

#	ARTICLE	IF	CITATIONS
217	Genome-Wide DNA Profiling Identifies a Stable Profile Although with Aberrations Targeting the Fibroblast Growth Factor Pathway in Hairy Cell Leukemia.. Blood, 2007, 110, 4698-4698.	0.6	0
218	Molecular and Clinical Features of B Cell Chronic Lymphocytic Leukemia (CLL) Carrying Stereotyped B Cell Receptors: An Italian Experience.. Blood, 2007, 110, 3089-3089.	0.6	0
219	Low Dose Oral Fludarabine Plus Cyclophosphamide in Elderly Patients with Untreated and Refractory Chronic Lymphocytic Leukemia.. Blood, 2007, 110, 2055-2055.	0.6	0
220	Equivalent Efficacy and Lower Toxicity of Subcutaneous Cladribine at Reduced Doses (Five versus) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Italian Cooperative Group on Hcl. Blood, 2008, 112, 3174-3174.	0.6	0
221	Genome Wide-DNA Profiling of Richterâ€™s Syndrome-Diffuse Large B-Cell Lymphoma (RS-DLBCL): Differences with De Novo DLBCL and Possible Mechanisms of Transformation from Chronic Lymphocytic Leukemia (CLL).. Blood, 2008, 112, 2067-2067.	0.6	0
222	Multivariate Analysis of Prognostic Factors in CLL: A Study on 431 Patients Showing Usefulness of Novel Biological and Old Clinical Parameters in Predicting Shorter Survival: An Italian Multicentric Study. Blood, 2008, 112, 3143-3143.	0.6	0
223	Usage of IGHV4-39 with Stereotypic B Cell Receptor Is An Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. Blood, 2008, 112, 778-778.	0.6	0
224	The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia (CLL) Is Independent of del17p13: Implications for Overall Survival and Chemorefractoriness. Blood, 2008, 112, 3137-3137.	0.6	0
225	Impaired Expression of p66Shc, a Novel Regulator of B-Cell Survival, in Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 801-801.	0.6	0
226	Angiopoietin-2 Plasma Dosage Predicts Time to First Treatment (TTFT) and Overall Survival (OS) in Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 1260-1260.	0.6	0
227	The Normal IGHV1-69-derived B Cell Repertoire Contains â€œStereotypicâ€•Patterns Characteristic of Unmutated CLL.. Blood, 2009, 114, 4370-4370.	0.6	0
228	B-Cell Chronic Lymphocytic Leukemia Cells Exposed to the Non-Genotoxic p53 Activator Nutlin-3 Are Characterized by a Specific Gene Expression Signature.. Blood, 2009, 114, 4374-4374.	0.6	0
229	Host Genetic Background and Risk of Richter Syndrome: The Genotype of LRP4 Is An Independent Predictor of Chronic Lymphocytic Leukemia Transformation to Aggressive Lymphoma.. Blood, 2009, 114, 2340-2340.	0.6	0
230	The Host Genetic Background of DNA Repair Mechanisms Represents An Independent Predictor of Progression and Survival in Diffuse Large B-Cell Lymphoma Treated with R-CHOP.. Blood, 2009, 114, 442-442.	0.6	0
231	High Resolution Array-CGH Provides New Insights Into the Prognosis of Chronic Lymphocytic Leukemia (CLL): Is 8p Loss Worse Than 17p Loss?.. Blood, 2009, 114, 2339-2339.	0.6	0
232	Stereotyped Patterns of HCDR3 Sequences in Splenic Marginal Zone B-Cell Lymphoma (SMZL): SMZL-Biased Subsets Are Associated with a Worse Outcome.. Blood, 2009, 114, 760-760.	0.6	0
233	Identification of New Recurrent Multiple Small Interstitial Deletions Affecting Genes Coding for Kinases in Chronic Lymphocytic Leukemia (CLL): a New Pathogenic Mechanism?.. Blood, 2009, 114, 672-672.	0.6	0
234	13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia. Blood, 2010, 116, 3578-3578.	0.6	0

#	ARTICLE	IF	CITATIONS
235	The Molecular Profile of Richter Syndrome Predicts Survival From Transformation: The Role of Clonal Relationship. Blood, 2010, 116, 3601-3601.	0.6	0
236	“Early-FDG-PET” but Not Macrophage Infiltration In Diagnostic Specimen Seems to Predict Clinical Course of Hodgkin Lymphoma. Blood, 2010, 116, 4826-4826.	0.6	0
237	The Genotype of MLH1 Is An Independent Predictor of Outcome In Diffuse Large B-Cell Lymphoma Treated with R-CHOP: a Training-Validation Study. Blood, 2010, 116, 992-992.	0.6	0
238	Molecular Cytogenetics Analysis of 13q14 Biallelic Deletion in Chronic Lymphocytic Leukemia: A Study on 250 Patients. Blood, 2011, 118, 1454-1454.	0.6	0
239	Mutations of NOTCH1 Are An Independent Predictor of Survival in Chronic Lymphocytic Leukemia. Blood, 2011, 118, 283-283.	0.6	0
240	A Prospective, Multi Center Phase II Study Evaluating Predictive Factors for Lenalidomide Treatment in Relapse or Refractory Chronic Lymphocytic Leukemia Patients (LE.P.RE.): Preliminary Results about the First 20 Enrolled Patients. Blood, 2011, 118, 1782-1782.	0.6	0
241	Disruption of BIRC3 associates with Fludarabine Chemorefractoriness in TP53 Wild Type Chronic Lymphocytic Leukemia. Blood, 2011, 118, 466-466.	0.6	0
242	Hairy Cell Leukaemia Displaying Multiple Surface Immunoglobulin Isotypes Reveal a Functional B-Cell Receptor In Which Isotype Roles Differ. Blood, 2011, 118, 1567-1567.	0.6	0
243	Phenethyl Isothiocyanate (PEITC) Regulates Autophagy in Chronic Lymphocytic Leukemia.. Blood, 2012, 120, 2906-2906.	0.6	0
244	Integrated Mutational and Cytogenetic Analysis Identifies New Prognostic Subgroups in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 712-712.	0.6	0
245	Genome-Wide Promoter Methylation Profiling Of Splenic Marginal Zone Lymphoma (SMZL) Identifies Two Subgroups Of Patients With Distinct Genetic and Biologic Features and Different Outcomes. Blood, 2013, 122, 77-77.	0.6	0
246	B Cell Receptor with Variant Surface Isotypes Transduce Functional Signals by Elevating Phospho-ERK1/2 Levels in Hairy Cell Leukemia with Mutant BRAF. Blood, 2013, 122, 1772-1772.	0.6	0
247	Genome-Wide Promoter Methylation Of Hairy Cell Leukemia (HCL). Blood, 2013, 122, 3757-3757.	0.6	0
248	Modulation of B Cell Receptor Signalling By IL-4 In Chronic Lymphocytic Leukaemia. Blood, 2013, 122, 4125-4125.	0.6	0
249	Surface IgM Levels Independently Influence Clinical Behavior and Associate with Altered Phenotype and Genetics in Chronic Lymphocytic Leukemia. Blood, 2014, 124, 830-830.	0.6	0
250	Increased Reactive Oxygen Species and the B-Cell Receptor in Chronic Lymphocytic Leukemia Signaling. Blood, 2014, 124, 3291-3291.	0.6	0
251	IL-4 Exerts Opposing Effects on Surface-IgM and CXCR4 Mediated Signalling in Chronic Lymphocytic Leukaemia. Blood, 2014, 124, 3299-3299.	0.6	0
252	The Dual PI3K/mTOR Inhibitor PF-04691502 Induces Substantial Apoptosis in Chronic Lymphocytic Leukemia Cells in Vitro and Prolongs Survival in the Eµ-TCL1 Mouse Model. Blood, 2014, 124, 832-832.	0.6	0

#	ARTICLE	IF	CITATIONS
253	A Molecular Model to Predict Durable Remission after First Line Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 3300-3300.	0.6	0
254	IL-10 Production By CLL Cells Is Enhanced in the Anergic IGHV Mutated Subset and Associates with Reduced DNA Methylation of the IL-10 Locus. <i>Blood</i> , 2015, 126, 2917-2917.	0.6	0
255	Biological Significance of B Cell Receptor Mediated Regulation of Autophagy in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 4130-4130.	0.6	0
256	Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 365-365.	0.6	0
257	Regulation of B-Cell Receptor Signalling By the Tumour Microenvironment in Chronic Lymphocytic Leukemia (CLL) and Its Impact on Adhesion and miRNA Expression. <i>Blood</i> , 2016, 128, 351-351.	0.6	0
258	A Distributed International Patient Data Registry for Hairy Cell Leukemia. <i>Blood</i> , 2016, 128, 5986-5986.	0.6	0
259	PI3K γ Inhibition Elicits Anti-Leukemic Effects through Bim-Dependent Apoptosis. <i>Blood</i> , 2016, 128, 3241-3241.	0.6	0
260	Early Enhancement of IgM Expression and Signaling Capacity during Ibrutinib Therapy in CLL Patients. <i>Blood</i> , 2016, 128, 4381-4381.	0.6	0
261	Acquisition of Mannoses on the Surface Immunoglobulin Binding Site Reveals Functional Status and Cell of Origin in Diffuse Large B Cell Lymphomas. <i>Blood</i> , 2018, 132, 677-677.	0.6	0
262	Immunoglobulin Variable Region Gene Sequences Reveal N-Glycosylation Motifs As an Early and Stable Event in Follicular Lymphoma Pathology. <i>Blood</i> , 2018, 132, 4101-4101.	0.6	0
263	PF526 STRUCTURAL AND FUNCTIONAL VARIABILITY OF THE TUMOR Bâ€CELL RECEPTOR INDICATES A ROLE FOR ENVIRONMENTAL INFLUENCES ON BEHAVIOR OF MANTLE CELL LYMPHOMAS. <i>HemaSphere</i> , 2019, 3, 215-216.	1.2	0
264	Neutropenia analysis of venetoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: Pooled data from VENICE-I and -II Phase IIIb trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20011-e20011.	0.8	0
265	Targeting Metabolic Alterations in CLL Microenvironment; Inhibition of Glutamine Import Attenuates Venetoclax Resistance. <i>Blood</i> , 2021, 138, 3717-3717.	0.6	0
266	Selinexor Enhances NK Cell Activation Against Lymphoma Cells Via Downregulation of HLA-E. <i>Blood</i> , 2021, 138, 2411-2411.	0.6	0
267	Low-grade non Hodgkin's lymphomas in the elderly: impact of a low-dose fludarabine-based combination regimen (mini-FLEC). <i>Haematologica</i> , 2003, 88, 358-60.	1.7	0